Head and Neck Cancer Market is expected to growth at USD 1.86 Billion at a CAGR of 7.40% during the forecast period 2022-2030.
Head and Neck Cancer Market Overview The Head and Neck Cancer Market is expected to reach USD 1.86 Billion by 2030 at 7.40% CAGR during the forecast period 2022-2030. Squamous cells that line the mucosal surfaces of the head and neck, such as the inside of the mouth, nose, and throat, are the origin of head and neck cancer. The oral cavity, pharynx, larynx, paranasal sinuses, and nasal cavity, as well as the salivary glands, are all affected by head and neck cancers. The two most common risk factors for head and neck cancer are alcohol and tobacco. Consumption of preserved or salted foods, occupational exposure to wood dust, Epstein-Barr virus infection, and poor oral hygiene are all risk factors for head and neck malignancies. The increased occurrence of head and neck malignancies is cited as the primary driver of the head and neck cancer market. Other factors such as the aging population, large oncology research funding, unmet medical requirements, increased market competition, better regulatory framework, aging population, and increasing government aid are all contributing to the global head and neck cancer market's growth. Despite these factors, there are still concerns about the head and neck cancer industry. The high cost of therapy, the negative effects of current treatment options, the absence of healthcare coverage, and the bad healthcare system in low- and middle-income countries may stifle market growth.
Head and Neck Cancer Market Segmentation
The head and neck cancer drugs market is segmented on the basis of the type of head and neck cancer diagnosis, treatment type, and end-user.
On the basis of the type of head and neck cancer market is classified as laryngeal cancer, pharyngeal cancer, salivary gland cancer, lip and oral cavity cancer, nasopharyngeal cancer, and others.
On the basis of diagnosis, the market is classified as bioscopy screening tests, blood tests, dental diagnosis, imaging, and endoscopy. The bioscopy screening tests are further classified as incisional biopsy, fine needle aspiration biopsy, and HPV testing. The blood tests are further classified as total cell count tests, liver function tests, and EBV antibody measurement. The dental diagnosis is further classified as fluorescence visualization, toluidine blue dye-based method, acetic acid rinse method, and brush biopsy. The imaging is further classified as PET/CT, MRI, X-ray, and Barium Swallow test. The endoscopy is further classified as pharyngoscopy, laryngoscopy, and others.
On the basis of treatment type, the head and neck cancer market is classified as chemotherapy, surgery, radiation therapy, targeted therapy, and others. The radiation therapy is further classified as external beam radiation and internal radiation therapy.
On the basis of end-user, the market is classified as hospitals, specialty clinics, and ambulatory surgical centers.
Head and Neck Cancer Market Regional Analysis
The Americas dominate the head and neck cancer market owing to the presence of patient population, increasing prevalence of head and neck cancer, well-developed technology, high healthcare expenditure, and the presence of leading market players. The head and neck cancer accounts for nearly 3% of all the cancers in the United States. In 2017, around 63,030 people developed head and neck cancer.
Europe holds the second position in the head and neck cancer drugs market. It is expected that the research and development expenditure provided by the government and private associations, increasing competition among marketers, rising healthcare expenditure, and amendments in reimbursement policies in healthcare are likely to drive the European head and neck cancer market.
Asia Pacific is the fastest growing market owing to a huge patient pool, increasing demand, and development of the healthcare technology.
The Head and Neck Cancer Alliance (HNCA) and PDS Biotechnology Corporation formed a partnership in May 2021. This collaboration aims to increase awareness of new and developing treatment options for people who have been diagnosed with HPV-related head and neck cancer, including clinical studies that are currently being conducted.
Tipifarnib (Kura Oncology) was designated as a Breakthrough Therapy by the Food and Drug Administration (FDA) in February 2021 for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma who have a variant allele frequency greater than or equal to 20% after platinum-based chemotherapy.
Head and Neck Cancer Market Key Players
Some of the key players in the global head and neck cancer market are AB Science SA, AbbVie Inc., Acceleron Pharma, Inc., AdDent Inc., ASAHI Roentgen, Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Carestream, Fujifilm Holdings, GE Healthcare, Identafi, Koninklijke Philips N.V., NeuSoft, Shimadzu Corporation, Siemens Healthcare, Varian Medical Systems, Xoran, and others.
|Market Size||USD 1.86 Billion|
|Key Market Opportunities|
|Key Market Drivers|
Leading players in the Market include AbbVie, Boston Biomedical, and Bayer AG, among others.
Global Market is expected to exhibit a strong 7.4% CAGR over the forecast period from 2022 to 2030.
Growing awareness about cancer is the major driver for the Head and Neck Cancer drugs Market.
The Americas dominate the Global Market.
Major types of head and neck cancer include salivary gland, laryngeal, pharyngeal, oral cavity, and nasopharyngeal.